@article{ref1,
title="Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion",
journal="Respiratory medicine case reports",
year="2019",
author="Tello, K. and Hoffmann, A. and Beutel, B. and Greulich, T. and Vogelmeier, C.F. and Richter, M.J. and Kuhnert, S. and Böselt, T. and Alter, P. and Holland, A. and Idzko, M. and Buhl, R. and Koczulla, A.R.",
volume="28",
number="",
pages="-",
abstract="We report about a case of a compassionate off-label use of the anti-interleukin-5-agent mepolizumab in a ventilated patient with life-threatening asthma attack in eosinophilic asthma. The patient suffered from severe eosinophilic asthma and was transmitted to our hospital with an asthma attack and a life-threatening respiratory state under ventilation. Since high dose steroids had not yielded a sufficient respiratory improvement mepolizumab was administered subcutaneously. After administration of mepolizumab respiratory state and ventilation parameter improved significantly. Two days after administration the patient was weaned could be extubated 8 days later and recovered completely from the asthma attack. The presented clinical case is suggestive of future clinical trials or registry studies to evaluate potential clinical benefits of anti-interleukin-5 treatment in patients with severe exacerbations of eosinophilic asthma. © 2019 The Authors<p /><p>Language: en</p>",
language="en",
issn="2213-0071",
doi="10.1016/j.rmcr.2019.100927",
url="http://dx.doi.org/10.1016/j.rmcr.2019.100927"
}